CLINICAL TRIALS PROFILE FOR FOSMIDOMYCIN
✉ Email this page to a colleague
Clinical Trials for Fosmidomycin
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00214643 ↗ | Efficacy of Fosmidomycin-Clindamycin for Treating Malaria in Gabonese Children | Completed | Albert Schweitzer Hospital | Phase 3 | There is a necessity for the development of new malaria drugs. Some antibiotics are also effective against malaria parasites. Fosmidomycin is an antibiotic that has been shown to be effective against malaria, although it cannot achieve a total cure in all patients. Previous small studies have shown that in combination with clindamycin, an commonly used antibiotic, it is highly effective and safe when given for three days, leading to a total cure in most patients. The current study will evaluate its efficacy in a larger population in Gabon, and compare its effect with the generally used drug, sulfadoxine-pyrimethamine. |
| NCT00217451 ↗ | Treatment of Malaria in Gabon With Fosmidomycin-Clindamycin | Completed | Albert Schweitzer Hospital | Phase 2 | Some antibiotics are also effective against malaria parasites. Fosmidomycin is an antibiotic that has been shown to be effective against malaria, although it cannot achieve a total cure in all patients. A previous small study has shown that in combination with clindamycin, an commonly used antibiotic, it is highly effective and safe, in asymptomatic carriers of malaria parasites. The current study will evaluate the efficacy and safety of the combination given for three days in children with uncomplicated malaria in Gabon. |
| NCT01002183 ↗ | Fosmidomycin With Clindamycin or With Clindamycin Plus Artesunate | Withdrawn | Mahidol University | Phase 2 | The aim of this study is to evaluate the role of clindamycin and artesunate as possible combination partners for fosmidomycin to protect it from its susceptibility to recrudescent infections when used as monotherapy for acute Plasmodium falciparum malaria while retaining its excellent safety profile |
| NCT01002183 ↗ | Fosmidomycin With Clindamycin or With Clindamycin Plus Artesunate | Withdrawn | Thammasat University | Phase 2 | The aim of this study is to evaluate the role of clindamycin and artesunate as possible combination partners for fosmidomycin to protect it from its susceptibility to recrudescent infections when used as monotherapy for acute Plasmodium falciparum malaria while retaining its excellent safety profile |
| NCT01002183 ↗ | Fosmidomycin With Clindamycin or With Clindamycin Plus Artesunate | Withdrawn | Jomaa Pharma GmbH | Phase 2 | The aim of this study is to evaluate the role of clindamycin and artesunate as possible combination partners for fosmidomycin to protect it from its susceptibility to recrudescent infections when used as monotherapy for acute Plasmodium falciparum malaria while retaining its excellent safety profile |
| NCT01361269 ↗ | Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria | Unknown status | Albert Schweitzer Hospital | Phase 2 | Few efficient drugs for malaria treatment are available so far. Due to increased exposure of these drugs and due to the high risk of development of drug resistant strains of Plasmodium falciparum, new drug combinations have to be actively investigated. The investigators will test the efficiency, safety and tolerance of combined fosmidomycin and clindamycin treatment in acute uncomplicated malaria in children aged 3-10 years. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Fosmidomycin
Condition Name
Clinical Trial Locations for Fosmidomycin
Clinical Trial Progress for Fosmidomycin
Clinical Trial Phase
Clinical Trial Sponsors for Fosmidomycin
Sponsor Name
